PSDV
$1.09
Psivida Corp Com
$.01
.93%
PSDV
Earnings Whisper ®
N/A
2nd Quarter December 2017
Consensus:  ($0.15)
Revenue:  $0.50 Mil
Tuesday
Feb 6
6:25 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when PSDV reports earnings?
Beat
Meet
Miss

Where is PSDV's stock price going from here?
Up
Flat
Down
Stock chart of PSDV
Analysts
Summary of analysts' recommendations for PSDV
Score
Grade
Pivots
Resistance
$1.15
$1.13
$1.11

$1.09

Support
$1.07
$1.05
$1.03
Tweet
Growth
Description
pSivida Corp., a specialty pharmaceutical company, combines existing drugs with its sustained release delivery technologies to develop transformational products primarily in ophthalmology. pSivida's two proprietary technology systems are Durasert and Tethadur. Durasert delivers specific quantities of drugs at controlled rates for predetermined periods of time from weeks to months. pSivida has developed three of the four sustained delivery release devices for retinal diseases that have been approved in either the US or Europe, the most recent being ILUVIEN?, partnered with Alimera Sciences and approved in multiple EU countries. Independently, pSivida is developing an injectable, bioerodible product to treat glaucoma and ocular hypertension. Tethadur is a protein, peptide and antibody delivery system.
Peers
IlluminaPerkinElmerAgilent TechnologiesCoherentBio-Rad LaboratoriesHarvard BioscienceAnalogic